Rainbow Children's Medicare Limited (NSE:RAINBOW)
India · Delayed Price · Currency is INR | Market Cap | 128.29B -15.2% |
| Revenue (ttm) | 16.13B +8.5% |
| Net Income | 2.58B +8.2% |
| EPS | 25.23 +7.6% |
| Shares Out | 101.56M |
| PE Ratio | 50.07 |
| Forward PE | 42.03 |
| Dividend | 3.00 (0.23%) |
| Ex-Dividend Date | Jun 27, 2025 |
| Volume | 108,942 |
| Average Volume | 198,007 |
| Open | 1,295.30 |
| Previous Close | 1,294.50 |
| Day's Range | 1,258.90 - 1,307.00 |
| 52-Week Range | 1,084.00 - 1,645.70 |
| Beta | 0.13 |
| RSI | 61.00 |
| Earnings Date | May 19, 2026 |
About NSE:RAINBOW
Rainbow Children's Medicare Limited operates a multi-specialty paediatric, obstetrics, and gynaecology hospital chain in India. The company offers medical and healthcare services to children and women. It also provides pediatric services under brand Rainbow Children’s Hospital which include newborn and pediatric intensive care; pediatric multi-specialty services; and pediatric quaternary care, such as multi-organ transplantation. In addition, the company offers women care services under Birthright brand that comprise perinatal care services, su... [Read more]
Financial Performance
In fiscal year 2025, NSE:RAINBOW's revenue was 15.16 billion, an increase of 16.88% compared to the previous year's 12.97 billion. Earnings were 2.43 billion, an increase of 12.18%.
Financial StatementsNews
Rainbow Children's Medicare Transcript: Q3 25/26
Q3 FY26 saw 12% revenue growth and strong new unit ramp-up, despite seasonal volume softness and increased competition. Occupancy was 47.2%, with a focus on driving this to 55-60% next year through digital, marketing, and specialty expansion. Cash reserves and capex plans remain robust.
Rainbow Children's Medicare Transcript: Q2 25/26
Q2 FY26 saw 6.5% revenue growth but lower occupancy due to seasonality, with strong specialty and IVF growth. Integration of new acquisitions and hospital expansions continue, supported by a robust net cash position and a 20% revenue CAGR target over the next 2–3 years.
Rainbow Children's Medicare Transcript: Q1 25/26
Revenue grew 7% YoY to INR 353 crores, with EBITDA up 11% and PAT up 35%. Expansion continued via acquisition and new projects, while mature hospitals saw muted volumes but strong specialty mix. Guidance remains for late teens to 20% revenue growth, with robust cash reserves and asset-light expansion.
Rainbow Children's Medicare Transcript: Q4 24/25
Q4 FY25 saw 8.5% revenue growth and 10.7% PAT growth, with strong cash generation and robust expansion plans. Mature hospitals maintained high occupancy, IVF revenue surged, and margin guidance remains at 25%+ despite new bed additions.
Rainbow Children's Medicare Transcript: Q3 24/25
Q3 FY25 delivered 18.5% revenue growth and 14% EBITDA growth year-over-year, with strong performance from both mature and new hospitals. Expansion plans remain on track, though international business faces headwinds and new projects like Gurgaon will be asset-heavy.
Rainbow Children's Medicare Transcript: Q2 24/25
Q2 FY25 saw 25.5% revenue growth and record profitability, driven by strong performance in mature and new hospitals, robust IVF growth, and disciplined cost management. Expansion continues with 380 new beds planned, while international business faces geopolitical headwinds.
Rainbow Children's Medicare Transcript: Q1 24/25
Q1 FY25 saw 15% revenue growth and strong operational metrics, with new hospitals expanding capacity but impacting margins due to higher costs. Occupancy and patient volumes improved, and margin recovery is expected as new units ramp up and break even.